-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The first new coronavirus vaccine officially approved by the FDA
On August 23, 2021, the U.
The vaccine is officially approved by the FDA to prevent new coronavirus infections in people aged 16 and over.
Since obtaining emergency use authorization in the United States on December 11, 2020, BioNTech has stated that it has provided more than 1.
Fosun Pharma participates in global joint research and development
Fosun Pharma participates in global joint research and developmentMany people may not know that there are also Chinese pharmaceutical companies in the first new crown vaccine officially approved by the FDA
As early as March 2020, Fosun Pharma announced a strategic cooperation agreement with BioNTech of Germany.
Ugur Sahin, MD, CEO and co-founder of BioNTech, said: "The FDA's full approval of the vaccine today once again highlights its efficiency and safety
BioNTech is the holder of a marketing authorization in the United States, the European Union and the United Kingdom, and an emergency use authorization or equivalent authorization holder in the United States (in conjunction with Pfizer), Canada and other countries
In the process of global joint research and development, Fosun Pharma and the Chinese Academy of Medical Sciences have completed animal trials of multiple mRNA candidate vaccines, and conducted in-depth cooperation with Germany in clinical research, pharmacological data, pharmacovigilance and other aspects
The successful development of the mRNA new crown vaccine contains the wisdom of the Chinese scientific research team and is also one of the model projects of Sino-German scientific research cooperation
Localized production is progressing rapidly
According to previous public reports, the rights and interests of this vaccine in mainland China and Hong Kong, Macao and Taiwan are exclusively owned by Fosun Pharma
In the first half of 2021, the vaccine has been approved for emergency use in Hong Kong, China and approved for import with a special license from Macau, China, and has been put into government vaccination programs in Hong Kong and Macau, China
According to the 2021 semi-annual report disclosed by Fosun Pharma on August 23, as of August 20, a total of 4.
In addition, Fosun Pharma intends to supply 15,000 doses of mRNA COVID-19 vaccine to Taiwan, China.
What's more worth mentioning is that the localized production of this vaccine is progressing very rapidly
What's more worth mentioning is that the localized production of this vaccine is progressing very rapidly
.
In May 2021, Fosun Pharmaceutical Industry and BioNTech reached an intention to establish a joint venture company to further implement the localized production of mRNA COVID-19 vaccine
.
According to the agreement, Fosun Pharmaceutical Industry and BioNTech intend to subscribe to 50% of the registered capital of the joint venture
.
Among them, Fosun Pharmaceutical Industry intends to make capital contributions in cash and/or tangible or intangible assets (including plant and production facilities, etc.
), and BioNTech intends to make capital contributions in intangible assets such as related production technology and proprietary technology licenses
.
According to the announcement, Fosun Pharma will provide an annual production capacity of 1 billion doses of mRNA COVID-19 vaccine production facilities
.
Once the domestic approval is passed, Fosun Pharma and BioNTech will quickly promote the localized production of vaccines in China and become a domestically produced mRNA vaccine
.
Up to now, matters related to the establishment of the joint venture company have yet to be further negotiated and signed by the two parties, and the final agreement shall prevail
.
At a time when the global epidemic is still raging, this news undoubtedly brings us hope
.
.
